An observational study in Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by Caribou Biosciences, Inc.. Enrolling by invitation at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Caribou Biosciences, Inc. · Observational
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
1,989 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 307 are open to participants now.
This study's planned enrollment of 150 is close to the median of 150 across 159 observational studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Caribou Biosciences, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who received IP in a Caribou-sponsored clinical study, special access program, or IIT and provided informed consent for the LTFS
Exclusion Criteria:
consent for the LTFS
Biological: Caribou-sponsored investigational therapy
N/A this is an observational study
Incidence of targeted NSAEs
Incidence of targeted NSAEs
Time frame: 15 Years
Frequency of targeted NSAEs
Frequency of targeted NSAEs
Time frame: 15 Years
Duration of targeted NSAEs
Duration of targeted NSAEs
Time frame: 15 Years
Outcome of targeted NSAEs
Outcome of targeted NSAEs
Time frame: 15 Years
Incidence of AESIs
Incidence of AESIs
Time frame: 15 Years
Frequency of AESIs
Frequency of AESIs
Time frame: 15 Years
Duration of AESIs
Duration of AESIs
Time frame: 15 Years
Outcome of AESIs
Outcome of AESIs
Time frame: 15 Years
Incidence of targeted SAEs
Incidence of targeted SAEs
Time frame: 15 Years
Frequency of targeted SAEs
Frequency of targeted SAEs
Time frame: 15 Years
Duration of targeted SAEs
Duration of targeted SAEs
Time frame: 15 Years
Outcome of targeted SAEs
Outcome of targeted SAEs
Time frame: 15 Years
Incidence of AEs related to IP leading to death
Incidence of AEs related to IP leading to death
Time frame: 15 Years
Overall survival
Assessment of overall survival and disease progression as described in the SOA
Time frame: 15 years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Caribou Biosciences, Inc.